Novartis moves to quash SCOTUS review of Entresto case

Pharma company tells court generics rival’s petition is “not the subject of any legal conflict”, as it reassures investors that a $12bn biotech acquisition will deliver growth.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Novartis stops rival’s launch of Entresto generic

16 January 2025 A district court of appeal has paused MSN Pharmaceuticals’ launch | Result comes days after the Federal Circuit restored Novartis’ patent and overturned a decision in favour of MSN | Request is one in a flurry of filings between the pair over the heart-failure drug.

Big Pharma

Novartis wins appeal in MSN clash over heart drug generic

14 January 2025 Federal circuit reverses district court’s ruling to revive combination patent | Novartis says patent has paediatric exclusivity expiring in July 2025.

More features

AZ counsel warns: EU Bolar exemption is ‘painful’ for pharma innovators

Pfizer beats Novo Nordisk in $10bn bidding war

‘I need them and they need me’: Regeneron counsel on what makes a strong law firm partnership

7 in-house counsel tips for partnering with AI vendors

Patent applications for bio-cosmetics double in five years

Sun Pharma and BMS lead 2025 ANDA litigation

Weil continues IP expansion as another litigator jumps from rival firm

WIPR Rankings reveals the go-to firms and attorneys for China patent work

Novartis moves to quash SCOTUS review of Entresto case

More on this story

Editor's picks

Editor's picks

More features